A Long-Acting Glucose-Dependent Insulinotropic Polypeptide Receptor Agonist Shows Weight Loss without Nausea or Vomiting
Friday, June 23, at 3:15 p.m. PT
San Diego Convention Center
Filip K. Knop, MD, PhD
Gentofte Hospital, University of Copenhagen
What is your presentation about?
In my presentation, I will share the first data on the safety of LY3537021, a potent, selective, long-acting (once-weekly administered) glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, in healthy people and in individuals with type 2 diabetes. The study is the first to describe the effects of prolonged supraphysiological GIP exposure in healthy people and in individuals with type 2 diabetes.
What makes this topic important in 2023?
The GIP receptor and glucagon-like peptide 1 (GLP-1) receptor co-agonist tirzepatide shows weight loss efficacy in people with type 2 diabetes, but the contributions of long-acting GIP receptor agonism to overall metabolic, glucose, and body weight effects remain unclear.
How did you become involved with this area of diabetes research or care?
Since the early 2000s, working with Tina Vilsbøll, Thure Krarup, Sten Madsbad, and Jens J. Holst as a young clinician scientist, I have been involved in studies investigating the effects of GIP in human physiology, GIP’s implications in diabetes pathophysiology and the therapeutic potential of GIP. We have published scores of papers on short-term GIP infusions in humans, but we have never had the tools to study prolonged supraphysiological GIP exposure in humans.
How do you think your presentation will impact diabetes research or care?
My presentation will provide information on the safety and pharmacokinetics of LY3537021; and hopefully, delegates will bring home a better understanding of the pharmacodynamics associated with prolonged supraphysiological activation of the GIP receptor in humans. Also, the presentation will shed light on how multi-agonist incretins such as tirzepatide work.
What are you most looking forward to at the 83rd Scientific Sessions?
I look forward to sharing and discussing new research on GIP with colleagues from around the globe. Also, a favourite ADA activity of mine is to stroll the poster hall, becoming impressed with the multifarious science and clever people presenting and sharing their passion.
Register to View the 83rd Scientific Sessions Virtual Program
Virtual registration is still an option to take advantage of the valuable content presented at the 83rd Scientific Sessions on the latest advances in diabetes research, prevention, and care. Access to the virtual program is available to registered participants June 27–August 28.